XML 47 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Redeemable Non-Controlling Interest
12 Months Ended
Dec. 31, 2020
Noncontrolling Interest [Abstract]  
Redeemable Non-Controlling Interest
20.Redeemable Non-Controlling Interest
    On March 5, 2019, the Company acquired Discovery Benefits, an employee benefits administrator. The seller of Discovery Benefits obtained a 4.9 percent equity interest in the newly formed parent company of WEX Health and Discovery Benefits (the “U.S. Health business”). The seller’s 4.9 percent non-controlling interest in the U.S. Health business was initially established at both carrying value and fair value. On the date of acquisition, the excess of the fair value of the 4.9 percent equity interest in WEX Health over its carrying value was recognized as an equity transaction, resulting in a $41.4 million increase to additional paid-in capital. Remeasurement of the equity interest to fair value during the first quarter of 2019 resulted in an increase to redeemable non-controlling interest of $41.4 million and an offsetting decrease to retained earnings that did not impact earnings per share.
    The agreement provides the seller with a put right and the Company with a call right for the equity interest, which can be exercised no earlier than seven years following the date of acquisition. Upon exercise of the put or call right, the purchase price is calculated based on a revenue multiple of peer companies (as described in the operating agreement for the U.S. Health business) applied to trailing twelve month revenues of the U.S. Health business. The put option makes the non-controlling interest redeemable and, therefore, the non-controlling interest is classified as temporary equity outside of stockholders’ equity.
The Company calculates the redemption value of the non-controlling interest on a quarterly basis using revenue multiples as determined in accordance with the operating agreement for the U.S. Health business and described above. The redeemable non-controlling interest is reported at the higher of its redemption value or the non-controlling interest holder’s proportionate share of the U.S. Health business’ net carrying value. Any resulting change in the value of the redeemable non-controlling interest will be offset against retained earnings and impact earnings per share.
    The following table presents the changes in the Company’s redeemable non-controlling interest:
Year Ended December 31,
 (In thousands)
20202019
Balance, beginning of year$156,879 $— 
Acquisition of Discovery Benefits at fair value 25,757 
Establishing redeemable non-controlling interest for WEX Health at carrying value 32,843 
Adjustment to redeemable non-controlling interest to reflect WEX Health at fair value 41,400 
Net income (loss) attributable to redeemable non-controlling interest652 (436)
Change in value of redeemable non-controlling interest(40,312)57,315 
Balance, end of year$117,219 $156,879